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In patients who undergo coronary artery bypass urgery, the 
internal mammary artery is considered to be the bypass 
conduit of choice. There is evidence (l-4) that, compared with 
saphenous vein grafts, internal mammary artery grafts improve 
long-term survival and decrease the incidence of recurrent 
angina nd cardiac events. This beneficial clinical outcome has 
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II clinical event rate 
been associated with superior early and late patency rates of 
internal mammary artery grafts. One year after operation, 76% 
to 93% of vein grafts are open and at the end of 10 years only 
41% to 63% remain patent (1, 5-7). The yearly attrition rate 
increases from 2% for the 2nd to 7th postoperative y ar to 5% 
over the next 5 years (5). In contrast, l-year and IO-year 
patency rates of internal mammary artery grafts are 88% to 
96% and 69% to 83%, respectively (1,6,7). Early vein graft 
occlusion is frequently due to thrombosis and probably intimal 
hyperplasia, whereas progressive atherosclerosis of the graft is 
the main determinant of late occlusion (5,6,8). Atherosclerosis 
has rarely been o!xerved in internal mammary artery grafts 
(5,6). 
It has been demonstrated persuasively (930) that patency 
of vein grafts at 1 year is improved by antiplatelet drclgs. 
Whether these or other antithrombotic drugs have fc similar 
favorable effect on internal mammary artery grafts iS not 
known. To compare the effects of various antithrombotic drug 
regimens in patients who had received internal mammary 
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artery grafts, we analyzed the data derived from CABADAS 
(Prevention of Coronary Artery Bypass Graft &!usion by 
&pifin, Dipyridamole and Acenocoumaro!/Phenprocoumon 
study) (11). The primary objective of this prospective, random- 
ized clinical trial was a comparison f the efficacy and safety 
of I) a low dose of aspirin, 2) a low dose of aspirin plus 
d@idamo!e, and 3) oral anticoagulant gents in the preven- 
tion of vein graft occlusion during the 1st year after coronary 
bypass surgery. Aspirin and aspirin plus dipyridamole w re 
compared ina placebo-controlled, double-blind design. Oral 
anticoagulant gents were valuated in a third open treatment 
arm because of logistic reasons associated with the necessary 
l&~rctrary control for dose adjustments in patients receiving 
these drugs, More than half of the patients received internal 
mammary artery grafts in addition to vein grafts. This sub- 
group was the subject of the present s udy. 
ieats. From July 1987 through August 1990,948 
underwent elective aortocoronaty bypass urgery 
with saphenous vein grafts for treatment of disabling angina 
were ntered into the trial by 10 participating hospitals. The 
present study group contained 494 of these patients who 
received internal mammaty artery grafts in addition to vein 
grafts. Exclusion criteria have been described indetail previ- 
ously (11) and included age >70 years; unstable angina or 
myocardia! infarction <2 and <7 days before operation, respec- 
tiveb previous orconcurrent cardiac operation; need for contin- 
ued antithrombotic drug therapy; increased risk of bleeding; 
known allew or intolerance to the trial medication; impaired 
renal or hepatic functian; concomitant severe disease, and allero 
to contrast agent impeding ability to repat coronary angiogra- 
phy. The use of previously prescribed antiplatelet drugs or ora! 
anticoagulant gents had to be discontinued 814 and ~5 days, 
respectively, &fore spention. All patients !!ave informed written 
taco! was approved by the ethics eommittee of 
Shyly medication, Patients were randomly allocated to 
receive ither aspirin plus dipyridamole placebo, aspirin plus 
dipyridamole, or oral anticoagulant gents. They were assigned 
to one of these drug regimens on the day before operation by 
the pharmacist of the participating hospital, according to a 
randomization listprovided by the study coordinating center. 
Patients were stratified by center, Treatment was tarted either 
before (dipyridamole, oral anticoagulant gents) or after (as- 
pirin) operation. Dipyridamole was administered by intnve- 
nOUs infusion (5 mg&g body weight per 24 h) from 8 PM on the 
day before operation until midnight after operation and was 
continued orally in a slow release form (200 mg twice daily). 
Treatment with aspirin (50 mg once daily) was started at 
midnight after operation; the first dose was administered 
through anasogastric tube. Ora! anticoagulant treatment was 
started on the day before operation and continued on the 1st 
postoperative day. The dose of oral anticoagulant agents, 
either acenocoumaro! or phenprocoumon, was adjusted to 
prothrombin times at a target range of international normal- 
ized ratio (INR) between 2.8 and 4.8. Antiplatelet drugs, 
unless assigned, were not allowed. Acetaminophen was pro- 
vided as a substitute for aspirin as analgesic. 
Surgery. lnterna! mammary artery grafts were imp!anted 
according to the routine techniques of each participating 
hospital. The decision to use these grafts was made by the 
surgeon before randomization. Internal mammary artery grafts 
were single (one distal anastomosis) or sequential (more than 
one distal anastomosis), and free grafts were used occasionally. 
The lumen of the grafted coronary artery was measured by 
calibrated probes at the xteriotomy site and as distally as 
possible. Endnterectomy was performed atthe discretion of
the surgeon if coronary arteries were 
administered during oFration, was 
sulfate at the end of the pr~ed~~e unless the i
intraaortic balloon pump required prolonged heparinizntion. 
Total postoperative blood loss through chest ubes and any 
required blood transfusions were recorded. 
Fo!~ow-us. After discharge front the !r ta!. follow-up 
visits were scheduled at3-month intervals coronary an- 
giography at 1 year after operation. A questionnaire was 
addressed to the cardiologist 1 year after operation if a patient 
had been withdrawn from the trial. At follow-up visits, clinical 
and !&oratory data were collected and an ~lectro~drdiogram 
(ECG) w corded. Compliance was assessed bypi!! count in 
both aspi roups. Prothrombin time was measured regularly 
in patients who received oral anticoagulant gents. Coronary 
angiography was not performed 1 year after oFration if it had 
been done for medical reasons ~3 months previously or if 
previous angiography already showed vein graft occlusion, a 
primary end paint of the vein graft patency study. 
Angiogmphic end points. Internal mammary artery grafts 
were visualized by selective injection. A graft was classified as 
undefined if selective injection failed for technical reasons and 
no retrograde filling of the graft with contrast agent at coro- 
nary angiography was demonstrated. A graft was defined as 
occluded if occlusion was visualized atselective injection. A 
distal anastomosis was defined as occluded if contrast agent 
failed to flow from the graft into the grafted artery. If a 
sequential graft was occluded at its origin, all associated distal 
anastomoses were considered occluded unless a retrograde 
flow of contrast agent from the grafted artery into the graft was 
demonstrated. 
Angiograms were reviewed by independent experienced 
cardiologists, members ofthe angiography classification com- 
mittee who had no knowledge of the patient’s group assign- 
ment, and a consensus was reached. 
C!!ru?eal nd points. Myocardia! infarction, thromboembo- 
lism, major bleeding and death were primary clinical end 
points. Myocardia! infarction was diagnosed according toECG 
criteria. Thromboembolism was established by appropriate 
techniques. Bleeding was defined as major if life-threatening 
or fatal and if blood transfusion r a repeat operation was 
necessary. Death was classified as cardiac, due to throm- 
bosis, due to bleeding or due to other causes, according to
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ings. SecQnda~ clinical en 
rent angina, heart failure and 
o the left anterior 
incidence events (secondary end 
coronary artery; 86% of sequential grafts were placed to a 
diagonal branch and then to the left anterior descending 
equally distributed among the groups. 
operation toangiography was 372 days 
a~~~tiollal analysis. Grafts were classified ilS occluded in 
patients who were withdrawn from the trial or died, unless 
showed patent grafts. atients who ~0~~~~~~~ fdllow- 
refused a~~iograpl~y and those in whom angiography 
ere substituted in the same way ifmyocardial ~farct~o~~ 
had been demonstrated during the study period. Clinical 
outcome was analyzed by comparison f 1) the incidence of
separate clinical end points, 2) the proportion ofpatients with 
at least one primary clinical end point, and 3) the proportion of
patients with any primary or secondary clinical end point. Tbe 
study comprised two evaluations a reflected by its design, 
which was double-blind and placebo-controlled forboth aspi- 
rin regimens and open for oral anticoagulant therapy. There- 
fore, aspirin plus dipyridamole v rsus aspirin and oral antico- 
agulant agents versus aspirin were compared separately. 
A difference was quantified by relative risk and the 
calculated 35% confidence interval ). If the 95% CI did not 
encompass 1, the difference was tatistically significant a  a 5% 
level (p < 0.05). 
grams were not available in 65 patients because ofdeath (n = 
6) withdrawal from the trial (n = 33) refusal of repeat 
angiography atcompleted follow-up (n = 23) or complications 
of the a~gio~rap~~ic procedure (n = 3). Patients were classified 
as l~avil~~ witb~raw~ if randomly assigned drug therapy was 
discol~ti~~~ed prematurely and angiography was not repeated. 
Reasons for withdrawal were the occurrence of a ~rirna~ 
clinical end point (a = 5) or drug ~~to~cra~lce (n = 2); me 
reasons (n = 3); logistic problems (n = 3); and the pati 
request (n = 20). Angiography was complicated bydissection 
of the iliac artery in two patients and transient ~e~ro~o~~c si 
after lidocaine in one patient. At angiographic assess 
8.9% of arterial grafts were classified as undefined. 
The treatment groups were compared with respect to 
baseline and surgical characteristics bythe chi-square test or 
the Fisher exact est for qualitative variables. The Student t test 
or the Mann-Whitney U test was used for quantitative ari- 
ables. Continuous variables, unless indicated, are expressed as
mean value 2 SD, A two-tailed p value < 0.05 is considered to 
indicate statistical significance. 
Graft patency. Graft occlusion rates are shown in Table 2. 
These data represent the results obtained from 302 single and 
120 seauential internal mammary artery grafts (in total 551 
distal anastomoses). Occlusion rates by distal anastomosis 
were 4.6% in the aspirin plus dipyridamole group and 6.8% in 
the oral anticoagulant group versus 5.3% in the aspirin group. 
At least one internal mammary artery graft was occluded in
5.6% of patients who received aspirin plus dipyridamole and 
8.4% of patients who received oral anticoagulant gents com- 
pared with 6.7% of patients who received aspirin (p = NS). 
Analysis of graft patency including patients who were not 
evaluable by angiography also showed no significant differ- 
ences. Occlusion rates by distal anastomosis were 14.4% 
(aspirin plus dipyridamole) and 13.2% (oral anticoagulant 
agents) versus 13.6% (aspirin). Graft occlusion was demon- 
strated in 14.1%, 13.9% and 14.5% of patients, respectively. 
Data analysis was performed according tothe intention to 
treat. Patients were excluded from analysis f they withdrew 
consent before the start of the trial medication or if they 
received only arterial grafts and thus did not meet the inclusion 
criterion of the vein graft patency study. 
Analysis ofsubgroups defined by type of graft, type of distal 
anastomosis, location of distal anastomosis and lumen diameter 
of the recipient coronary artery revealed nosignificant differences 
in occlusion rates between the two aspirin groups (Table 3). A 
risk-unadjusted comparison f oral anticoagulant gents with 
aspirin suggested improved patency of single grafts by aspirin and 
an opposite ffect for sequential grafts. Endarterectomy was
performed in eight vessels, representing 1.2% of all distal sites. 
None of the grafts to these arteries was occluded. 
Patients. Of 948 patients entered into the vein graft pa- Chest ube drainage was 1,111 i: 633 ml in the aspirin group, 
tency trial, 7 withdrew their consent before assigned treatment compared with 1,301 -t732 ml in the aspirin plus dipyridamole 
was started and 29 did not receive vein grafts. The internal group (p = 0.011) and 1,143 - 699 ml in the oral anticoagulant 
mammary artery was used as an additional bypass conduit in group (p = 0.948). The median transfusion requirement for 
494 of the remaining 912 patients. Their clinical and internal red blood cells was 1.0 (donor) U (range 0 to 20) in the aspirin 
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Table 1. Baseline Characteristics of 494 Patients 
Aspirin + 
Placebo 
Aspirin + 
Dipyridamole 
Oral 
Anticoagulant 
Agents 
Patients (no.) 173 163 158 
Age W 58 + 9 5x r 6 5s + 7 
weight (kg) 792 IO 78 2 10 79 It 10 
Height (cm) 174 + 7 173 -c 8 114 i: g 
Men (%) 89 86 91 
Angina (9WHA class) 
II (%) 33 26 21 
III (%) 55 58 54 
IV (%) 12 Ih 99 
Previous myocardial infilmlion (k) 54 4Y 95 
Hypcrtcnsion (%) 32 34 41 
Diakles mellitus (%) IO Y 90 
Hyperlipidemia (%) 41 35 43 
Smoking (%) 79 7R 8.9 
Medication before owration (%) 
Nitrates 78 77 I? 
Reta~blocting agents x2 72 78 
Calcium channel antagonists 62 59 63 
Lipid&nvering drugs I2 92 9u 
Oral anticoagulant agents* 14 97 29 
Plafelet inhibitors* 94 9s 96 
Total cholesterol (mmoUliter) 7.1 + 1.4t 9i.R * I.31 7.0 t 9.3 
HDL choksteml (mmoVliter) 9.0 2 0.3 1.0 ? 0.3 I.1 r 0.X 
Triglycerides (mmoUliter) 3.0 ?: 1.x 2.7 2 9.6 2.R z 9.x 
Internal mammary artery grafts 
Singk graftslpatient 0.7 0.8 0.8 
Sequential grafts/patient 0.3 0.3 0.3 
Distal anastomoses/patient 9.4 9.4 9.4 
Location of distal anastomosis (%) 
LAD bY tiY 68 
Diagonal branch 25 29 .?.: 
LCX 6 IO 7 
RCA 0 0 9 
Diameter of recipient artery (%) 
si.0 mm 5 6 3 
1.9-95 mm 42 36 39 
1.6-2.0 mm 39 44 43 
32.0 mm 14 94 95 
‘Oral anticoagulant agents and platelet inhibitors were discontinued at least 5 and 14 days before operation, 
wxc9ively. b = 0.0% comparing aspirin + dipyridamole and aspirin + placebo. Values are mean value 2 SD unless 
otherwise indicaled. HDL = highdensity lipoprotein; LAD - left anterior descending coronary artery: LCx = left 
CircUmfla coronary artery; !WIA da.% - New York Heart Association classification; RCA = right coronary artery. 
group Venus 2.0 U (range 0 to 10) in the aspirin plus 
dipyridamole giqup (p = 0.118) and 1.0 U (range 0to 13) in 
the oral anticoagulant group (p = 0.743). 
Cardiopulmonary bypass time was 95 2 28 min in the 
aspirin group versus 105 If: 38 min in the aspirin plus dipyrid- 
amole group (p = 0.005) and 97 t 30 min in the oral 
anticoagulant group (p = 0.501). Reoperation rates (within 
24 h) were 2.3% (aspirin), 6.1% (aspirin plus dipyridamole) 
and 4.4% (oral anticoagulant agents). Operative mortality 
glun 30 days) was 0.6%, 0.6% and O.O%, respectively (p = 
Clinical end points. Of 95 primary clinical end points, a 
majority (72%) occurred inthe perioperative period (within 30 
days after operation). Myocardial infarction, thrombosis and 
major bleeding were observed somewhat more frequently in
the aspirin plus dipyridamole group, as was major bleeding 
in the oral anticoagulant group, as compared with findings in 
patients who were treated with aspirin (Table 4). Only the 
difference between the two aspirin groups with respect to 
thrombosis reached statistical significance. Of six patients who 
died, three in each aspirin group, acardiac cause was found in 
four patients (two in each aspirin group), bleeding in one 
patient (aspirin only group) and thrombosis in one patient 
(aspirin plus dipyridamole group). Any primary clinical end 
point occurred in 13.3% (aspirin only), 23.3% (aspirin plus 
dipyridamole) and 17.1% (oral anticoagulant gents) of pa- 
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uency of internal Mann 
Orid 
Relative Risk; 
Aspirin + Aspirin + Anticoagui;mt _ 
9% Confidence ‘nterval p Value 
- 
Unit of AnaBysis PhCCh~ Dipyridamole Agcn1.z / I ! * i - 
Distlrl aniKtomuses~ 5x (I l/NC) 4.65 (X/174) 6.W (I I!lhl) 0.87: 0.33-2.31 1.30: 0.52-3.25 0.786 0.578 
Grafts 6.4% (W/157) 5.0% (?/139) 8.7% (11X6) 0.79; 0.31-2.02 1.37; 0.60-3.12 0.809 0.600 
Patienls 6.7% (10/150) 5.6% (7024) 8.4% (10/l 19) 0.85; 0.33-2.16 1.26; 0.54-2.93 0.922 0.760 
‘Aspirin + dipyridanlole versus aspirin f ph~eb. tOmI antxoaguiant agents versus aspirin + placebo. $Comparison by ratio estimate analysis. Values for the 
three treatment grot+ wptewt prrc~nt of grafls occluded and (in parentheses) number of occluded grafts/total number of grafts. 
tients. The relative risk for aspirin plus di~yri~amo~e versus 
aspirin was 1.75, 95% CI 1.09 to 2.81 (p = 0.025). 
Angina at any time during the foHow-up eriod was re- 
ported in 14.5% (aspirin only), 14.1% (aspirin plus dipyri- 
damole) and 16.5% (oral antico~g~~al~t agents) of patients. At 
the end of the 1st year 911.4%V 93.0% and 90.4% of the 
treatment groups, respectively, were free from angina. Wcnrt 
failure and symptomatic arrhythmias were observed less fre- 
quently in patients who rcccived aspirin. The ovverall cvcnl 
rate, including primary and secondary clinical end points, 
remained higher in the aspirin plus dipyridamole group. This 
difference was borderline significant for both aspirin groups 
(relative risk 1.34, 95% CI 0.99 to 1.81, p = 0.058). 
Compliance snd level of oraS aaticoagulation. Pill counts 
showed that 85% of the trial medication had been taken by 
patients in each aspirin group. Bn patients who received oral 
anticoagulant agents amean of 17 prothrombin time measure- 
ments/patient were performed over the follow-up period. The 
number of days spent within the target range of adequate 
anticoagulation (2.8 to 4.8 INR), expressed as percent of the 
total treatment time, averaged 54% of the follow-up period/ 
patient. Underanticoagulation (~2.8 INR) was found for 41% 
and overanticoagulation (>4.8 IN!) for 5% of the follow-up 
period/patient. 
Hn 76 patients, of whom 33 were withdrawn from the trial, 
assigllcd treatment was discontinued because of a primary 
clinical end point (n = l’d), drug intolerance (n = 22), medical 
reasons (n = 9), logistic reasons (n = 4) or the patient’s 
request (n = 22). Aspirin was discontinued in 26 patients 
(Ml%), aspirin plus dipyridamole in 34 (20.9%) and oral 
anticoagulant agents in 16 (10.1%). In 67 (88%) of the 76 
patients, the trial medication was replaced by anot 
thrombotic drug regimen that contained aspirin, dipyridamole 
or oral anticoagulant agents in various doses and combina- 
tions. Drug intolerance wac characterized by either headache 
or nausea with vomiting, or both, in 18 patients (6, aspirin plus 
lacebo; 12, aspirin plus dipyridamole), and allergy in 4 
patients (3, aspirin plus placebo: I, aspirin plus dipyridamole). 
Complaints disappeared in 19 patients whose treatment was 
continued with aspirin alone. 
Table 3. Frequency of internal Mammary Artery Graft Occlusion According to Type of Graft and Distal Anastomosis, Location of Distal 
Anastomosis and Coronary Artery Lumen h)iameter 
Single grafts 
Aspirin + Aspirin + 
Placebo Dipyridamole 
2.9? (3/105) 1.9% (2/105) 
Oral 
Anticoagulant 
Agents 
12.0% (I l/92) 
Relative Risk; 
95% Confidence interval 
* t 
0.67: 0.1 l-3.91 4.1x; 1.20-14.54 
p Value 
* i 
I .OOo 0.028 
Sequential grafts 
Grafts 13.5% (7/52) 14.7% (S/34) 0% (O/34) 1.09: 0.38~3.16 - I .uoo 0.039 
DisM anastomoses X.4% (c)/107) 8.6% (6/7(l) (1% (O/71) I .02: 0.38 -2.74 - I .ooo 0.012 
Distal aoastomoses 
End to side 4.5% (7/l%) 3.5% (5/142) 8.7% (I l/127) 0.78: 0.25-2.42 I .93: o-77- 4.83 0.898 0.235 
Side to side 7.3% (4/5.5) 8.6% (3/35) 0% (O/36) 1.18; 0.28-4.95 _- 1 .ono 0.150 
Location of distal anastomosis 
LAD 4.2% (61144) 4.8% (61126) 7.1% (W112) l.l4;0.38-3.6 1.71; 0.61 4.80 I.000 U.446 
Diagonal branch 7.0% (4/57) 6.1% (2/33) 2.6% (l/38) 0.86: 0.17- 4.46 0.3% 0.04-3.23 I ,000 0.645 
LCX 10.0% (ido) 0.0% (O/IX) 16.7% (2/12) - 1.67; o.wi5.xn 0.357 1 .wo 
RCA 0% (o/o) 0% (O/O) 0% (O/l) 
- - - 
Lumen diameter (mm) 
51.0 9.1% (I/II) 0.0% (win) 50.0% (2/4) - s.50; 0.67..45.37 1.000 0.154 
1.1-1.5 4.4~ (4190) 1.8% (l/57) I.9F (l/54) n.39; n.o5-3.44 0.42; n.o5-3.63 0.649 0.650 
1.6-2.0 h.K+ (5178) 8.0% (6/7S) 0.w ( 717 I ) 1.25; 0.40-3.92 1.54; 0.51-4.63 0.946 0.637 
>2.0 0% (O/24) 3.6% (l/28) 4.24 ( 1124) - - 1.000 1.000 
*Aspirin f dipyridamole versus aspirin + placebo. tOral anticoagulant agents versus aspirin + placebo. Values for the three treatment groups represent Percent 
of grafts occluded and (in parentheses) number of occluded grafts/total number of grafts. 
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Table 4. Occurrence of Primary and Secondary Clinical End Points 
Aspirin + Aspirin + 
Placebo Dipyridamole 
(n = 173) (n = 163) 
Oral 
Anticoagulant 
Agents 
(n = 158) 
Relative Risk: 
95% confidence interval 
‘y t 
p Value 
* i 
Primary clinical end point 
Myocardial infarction 8.7% (IS) 9.2% (15) 7.6% (12) 1.06; 0.54-2.10 0.W; 0.42-M 1.@?0 0.876 
Perioperative 7.5% (13) 6.7%(11) 5.7% (9) 0.90,0.41-1.95 0.76 0.33-1.72 0.952 0.658 
Thrombosis 0.4% (1) 4.9% (8) 1.3% (2) 8.49; 1.07-67.14 2.19; 0.20-23.92 0.017 0.607 
Periqxrative 0.6% (1) 1.2% (2) 0.6% (1) 2.1?;0.19-23.19 l.@ 0.07-17.36 0.613 1. 
Major bleeding 5.8% (10) Y.O% (13) 8.2% (13) l..W, 0.62-3.06 1.42: 0.64-3.15 0.562 0.510 
Perioperative CO% (3) 7.4% (Ii) 6.3% (IO) 1.82; 0.73-451 lS1i; 0.61-4.01 .’ 21 0.490 
Death 1.7% (3) 1.8% (3) 0% (0) I.&, 0.22-5.18 1.w 0. 
PwiopePiltivc 0.6% (1) 0.6% (1) 0% (0) 1.~;(~.~7-1~.~3 - 1 non 1. 
f3ewndrfy clhicut end point 
Angina 145% (25) 14.1% (23) 16.5% (26) 0.98; O.SR-1.65 l.lJ;O.69-1.89 1 .of?.o 0.725 
Heart failure 1.2% (2) 3.1% (5) 2.5% (4) 2.6% 0.52-13.49 2.19;0.41-11.79 0.271 0.430 
Arrhythmia 2.3% (4) 3.7% (6) 3.8% (6) kw: 0.46-5.51 l&k 0 G-571 0.532 0.528 
Any cliuical end point 
Primary 13.3% (23) 23.34 (38) 17.1% (27) 1.75: 1.01)-2.81 I.29; 0.77-2.15 0 025 0.4 I8 
Primary or xcnndaty 28.9% (SO) 3S.78 (63) 31.6% (SO) 1.3J; 0.9!w.sI 1.00;0.79-9.52 0.058 0.672 
‘Aspirin + dipyridamok versus aspirin + placcho. t&al anticoagulant agents versus aspirin + placebo. Values for the three treatment groups represent percent 
of events and (in prenthcses) numkr of events 
The present study shows imilar l-year patency rates of 
internal mammary artery grafts among patients who were 
treated with a low dose of aspirin (50 mglday) plus dipyri- 
damole, oral anticoagulant gents or aspirin alone. However, 
the addition of dipyridamole to aspirin was associated with an 
increased risk of clinical events. 
Antithrombotfc drutp. Aspirin was given in a lower dose 
ay) than is commonly used. This dose was based on 
ental evidence that 40 to 80 mg of aspirin is sufficient 
to inhibit plateiets hrough a decrease in the production f the 
atory platelet constituent thromboxane AZ and a less 
d inhibition of the endothelial production of its 
counterpart, prostacyclin (13). In the meantime, a low dose of 
has been demonstrated to be effective (14,lS) in 
with unstable angina (75 mglday) and in patients with 
transient ischemic attacks (30 mglday). A benefit has 
sted (16) after vein coronary bypass graft 
surgery (100 mglday). 
Dipyridamole was administered perioperatively by intrave- 
nous infusion and after operation by a slow release form in a 
dose of 200 mg twice daily. Both regimens differed from those 
used in previous trials and were designed to provide an 
appropriate assessment of the effects of this drug in combina- 
tion with aspirin. Dipyridamole is believed to potentiate he 
platelet-i~hi~~tin~ effect of aspirin, but the clinical relevance of 
this property remains controversial (17). We assumed that its 
vasodilating effect might be as or even more important, 
particularly in maintaining graft patency during and soon after 
coronary bypass surgery (18). Therefore, we preferred contin- 
uous intravenous infusion of dipyridamole to other modes of 
administration f r the perioperative period. 
tent a~titb~om~ti~ 
operation. The required Iaborato 
use of these drugs. Moreover, a beneficial effect on vein graft 
patency was not demonstrated when oral anticoagulant gents 
amole were compared (l&19). 
ncy. The presented I-year occlusion rates are in 
the range of previously reported rates of 4% to 12% (l&,7). It 
remains questionable whether the patency of internal mam- 
mary artery grafts is improved at all by antithrombotic drug 
therapy. Only Goldman et al. (20,21) have reported on this 
subject, and they found no differences in early and l-year 
patency rates of internal mammary artery grafts in patients 
receiving aspirin versus placebo. Because we had no placebo 
control group for ethical reasons, we were not able to assess 
the possible absolute benefit of the respective drug regimens. 
Nevertheless, oral anticoagulant agents howed a beneficial 
effect for sequential grafts in contrast to single grafts. This 
observation suggests a difference in the mechanism of throm- 
botic occlusion apparently related to the hemodynamic char- 
acteristics of these grafts, as most occlusions were found at 
similar distal sites on the left anterior descending coronary 
artery with a lumen diameter ~1.5 mm. Because ofhigh shear 
rates at distal sites, single grafts mighi be more prone to 
thrombosis that is mediated by deposition of platelets. By 
contrast, a fibrin clot might be propagated by lower shear rates 
at the distal sites of sequential grafts. 
In this study, patients received antithrombotic drugs for 1 
year, whereas graft patency was assessed only once at the end 
of the 1st postoperative year. This interval was based on the 
results of a previous vein graft patency trial conducted by 
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Chesebro et al. (!I), who demonstrated a significant reduction 
in graft occlusion rate between I month and 1 year in patients 
who received aspirin and dipyridamole for 1 year. Pfisterzr et 
orterl a similar benefit when they compared anti- 
thrombotic drug therapy given fcr 3 months versus I year. 
However, iCP0khnan et a!. (10) kwnd no reduction in new late 
graft occlusions after 1 year of aspirin therapy when they 
performed angiography wit&in 60 days and after 1 year. 
Goldman et al. (22) are the only workers who have studied the 
efiects of antithrombotic drug therapy continued for >I year, 
and they found no evidence that aspirin therapy continued 1to 
3 years postoperatively improved graft patency. A minimal 
treatment period of 1 year seems to be justified as long as more 
and unambiguous data are not available. 
Sequential grafts were used in 29% of all patients. These 
resented 40% to 50% of the patients randomized 
by three participating hospitals, but only 0% to 15% of the 
patients from the remailGug seven hospitals. At least some of 
these cardiac surgeons appiircntly preferred sequential to 
single internal llliillllnary artery grafts to obtain complete 
revascularization, but sly this policy is not yet common. 
Cliraical 0uueCJme. ences in clinical outcome between 
the three treatment groups were more pronounced. The 
incidence of myocardlal infarction and major bleeding tended 
to be slightly higher and the risk of thrombosis was greater in 
patients who received aspirin plus dipyridamole than in the 
aspirin group. The patients who received ipyridamole also 
had greater blood loss and transfusion requirements and more 
major bleeding necessitating reoperation. The increased risk of 
surgical bleeding is probably related to the perioperative 
infusion of dipyridamole. It may be due to vasodilation rather 
than to platelet inhibition, especially as platelet preservation by 
dipyridamole has been demonstrated (23) in patients after 
coronary bypass urgery. Surgical bleeding tended also to occur 
more frequently in patients who received oral anticoagulant 
agents than in those who received aspirin alone, but this 
difference was not reflected by blood loss and transfusion 
requirement. The risk of surgical bleeding probably remained 
limited by the delayed anticoagulant effect of these drugs, 
which were started on the day before operation. Overall, any 
primary clinical end point occurred more frequently if dipyr- 
idamolc was added to aspirin. In this respect, he aspirin and 
oral anticoagulant groups howed no significant difference. 
~i~i~~io~s and clinical implications. Our study was not 
adequately powered to detect small or even moderate differ- 
ences in occlusion rates, given the number of patients and 
the low occlusion rates. This is particularly a limitation of 
treatment comparisons within the subgroups. However, only 
large differences were considered clinically important. The 
observed ifferences were too small to be relevant, even if a 
larger sample size would reveal statistical significance. By 
contrast with such a potential and probably limited benefit, 
there was a 75% increase in risk of major clinical events if 
dipyridamole was added to aspirin. Oral anticoagulant agents 
provided no benefit with respect o graft patency and clinical 
outcome. Thus, aspirin plus dipyridamole had an unfavorable 
risk/benefit ratio, whereas the ratio was equal for oral antico- 
agulpnt agents and for aspirin. 
In patients who receive internal mammary artery grafts 
ex&sively in coronary bypass urgery, the need for antithrom- 
botic drug therapy has not yet been established. These grafts 
have a high patency rate even after 10 to 85 years9 and they are 
probably less prone than vein grafts to both early and late 
occlusion. The risk of early attrition by thromhosis may be 
reduced at least in part because internal mammary artery 
grafts are used preferentially tobypass large coronary arteries, 
in particular, the left anterior descending coronary artery. 
Long-term patency depends mainly on progressive atheroscle- 
rosis, which is uncommon i  internal mammary artery grafts. 
However, access of the internal mammary artery is limited and 
revascularization procedures tend to be more extensive. Thereby7 
a substantial number of patients till require vein grafts in 
addition to internal mammary artery grafts. This group may 
become smaller as sequential nd free internal mammary artery 
grafts, as well as other arterial bypass conduits like the gastroepi- 
~91oic xtts),, are applied more widely. However, as lolrg as vein 
crafts are required, patients will be treated with antithrombotic 
&gs that have been demonstrated o improve vein graft patency. 
With respect to efficacy, safety, feasibility and costs, low dose 
aspirin (50 r&day) is preferable toaspirin plus dipyridamole and 
to oral anticoagulant agents. 
Conclusionns. Internal mammary artery graft patency at 1 
year after coronary bypass urgery is not improved by dipyri- 
damole if this drug is added to a low do?: of aspirin 
(50 mg/day). Moreover, this combination ofdrugs is associated 
with an increased overall risk of major clinical events. Oral 
anticoagulant agents provide no benefit over that achieved 
with low dose aspirin. 
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